Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

Lim, L.S.; Mitchell, P.; Seddon, J.M.; Holz, F.G.; Wong, T.Y. Age-related macular degeneration. Lancet 2012, 379, 1728–1738.

[CrossRef]

Ohji, M.; Takahashi, K.; Okada, A.A.; Kobayashi, M.; Matsuda, Y.; Terano, Y.; ALTAIR Investigators. Efficacy and safety of

intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from

ALTAIR: A randomized controlled trial. Adv. Ther. 2020, 37, 1173–1187. [CrossRef]

Ramakrishnan, M.S.; Yu, Y.; VanderBeek, B.L. Association of visit adherence and visual acuity in patients with neovascular

age-related macular degeneration: Secondary analysis of the comparison of age-related macular degeneration treatment trial.

JAMA Ophthalmol. 2020, 138, 237–242. [CrossRef]

Heier, J.S.; Khanani, A.M.; Ruiz, C.Q.; Basu, K.; Ferrone, P.J.; Brittain, C.; Figueroa, M.S.; Lin, H.; Holz, F.G.; Patel, V.; et al. Efficacy,

durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA

and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials. Lancet 2022, 399, 729–740. [CrossRef]

Spaide, R.F.; Jaffe, G.J.; Sarraf, D.; Freund, K.B.; Sadda, S.R.; Staurenghi, G.; Waheed, N.K.; Chakravarthy, U.; Rosenfeld, P.J.;

Holz, F.G.; et al. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on

Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology 2020, 127, 616–636. [CrossRef]

Rush, R.B.; Rush, S.W. Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration. Clin. Ophthalmol.

2022, 16, 4041–4046. [CrossRef]

Stanga, P.E.; Valentín-Bravo, F.J.; Stanga, S.E.F.; Reinstein, U.I.; Pastor-Idoate, S.; Downes, S.M. Faricimab in neovascular AMD:

First report of real-world outcomes in an independent retina clinic. Eye 2023. Online ahead of print. [CrossRef]

Ahn, J.; Hwang, D.D.-J.; Sohn, J.H.; Son, G. Retinal pigment epithelium tears after anti-vascular endothelial growth factor therapy

for neovascular age-related macular degeneration. Ophthalmologica 2022, 245, 1–9. [CrossRef]

Chan, C.K.A.P.; Meyer, C.H.; Kokame, G.T.; Kaiser, P.K.; Rauser, M.E.; Gross, J.G.; Nuthi, A.S.; Lin, S.G.; Daher, N.S. Optical

coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears

associated with intravitreal bevacizumab injections. Retina 2010, 30, 203–211. [CrossRef]

Chan, C.K.M.C.; Gross, J.G.; Abraham, P.; Nuthi, A.S.; Kokame, G.T.; Lin, S.G.; Rauser, M.E.; Kaiser, P.K. Retinal pigment

epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007, 27, 541–551.

[CrossRef]

J. Clin. Med. 2023, 12, 5145

11.

12.

8 of 8

Chiang, A.; Chang, L.K.; Yu, F.; Sarraf, D. Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT

analysis. Retina 2008, 28, 1265–1269. [CrossRef]

Clemens, C.R.; Alten, F.; Eter, N. Reading the signs: Microrips as a prognostic sign for impending RPE tear development.

Acta Ophthalmol. 2015, 93, e600–e602. [CrossRef]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual

author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to

people or property resulting from any ideas, methods, instructions or products referred to in the content.

...